EGFR and non-small cell lung carcinoma: ,22 As of January 2021, lazertinib 240 mg once-daily treatment has been approved in the Republic of Korea for patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after EGFR TKI therapy.